Form 8-K Travere Therapeutics, For: Feb 20
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Travere Therapeutics (TVTX) PT Raised to $35 at Citi
February 24, 2025 4:58 AM ESTCiti analyst Carly Kenselaar raised the price target on Travere Therapeutics (NASDAQ: TVTX) to $35.00 (from $31.00) while maintaining a Buy rating.
The analyst comments "We anticipate continued growth for FILSPARI in 2025, driven by 1) expected approval in FSGS in 4Q25 with an sNDA... More
